Compass Pathways Plc - ADR Aktie News

COMPASS Pathways shares show an early bullish trend, with a falling-wedge breakout holding key long-term support and setting up higher targets ahead of late-February earnings.

Compass Pathways plc experienced an >80% rally since my last 'Hold' rating. CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Recent approval of JNJ's Spravato as a standalone product in treatment of TRD offers significant piggybacking opportunity for Compass.

COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression Transcript

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company's commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences: 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on Dec...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will...